Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. filed this Current Report on Form 8-K on May 13, 2021, to announce its financial results for the quarter ended March 31, 2021. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This 8-K serves as a notification that results were reported and directs readers to the press release furnished as Exhibit 99.1 for detailed financial data.
Material Changes
The filing does not contain specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The report explicitly states that the information in Item 2.02 and Exhibit 99.1 is not treated as "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference unless expressly stated in another filing.
Key Facts for Investor Verification
- Verify the specific financial results for the quarter ended March 31, 2021, by reviewing the press release attached as Exhibit 99.1.
- Confirm the company's cash position and burn rate, as these are not disclosed in the 8-K text.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Note that the information in this specific 8-K item is not subject to the liabilities of Section 18 of the Exchange Act.